Maternal Serum AFP

Test Code

CPT Codes
82105<br /> **This test is not available for California or New York patient testing. For New York patient testing use new test code 92788-Maternal Serum AFP (NY)**

AFP, Maternal Risk Interpretation

Preferred Specimen
1 mL serum collected in a serum separator tube (SST®)

Minimum Volume
0.5 mL

Other Acceptable Specimens
Red-top tube (no gel)

Prenatal risk assessment for open neural tube defects (NTDs).
For manual orders use “Maternal Serum Screen Requisition."

The MSAFP test in pregnant women should be performed between 15.0 and 22.9 weeks gestational age, although the optimal period is 15.0-16.9 weeks. This time frame allows sufficient opportunity for further diagnostic studies if the initial MSAFP results are abnormal. Specimens submitted before 15.0 weeks or after 22.9 weeks gestation cannot be properly evaluated. Because MSAFP test results are influenced by certain patient characteristics, the following data must be provided with the specimen in order to permit accurate interpretation of results: date of collection, patient’s (maternal) date of birth, patient’s estimated date of delivery (EDD), patient’s weight (in lbs.), patient’s race, patient diabetic status (is patient insulin-dependent prior to pregnancy), number of fetuses, and whether this is a repeat sample.

Transport Container
Plastic screw-cap vial

Transport Temperature
Room temperature

Specimen Stability
Room temperature: 14 days
Refrigerated: 14 days
Frozen: 45 days

Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Grossly lipemic

Immunoassay (IA)

Setup Schedule
Set up: Mon-Sat; Report available: 3-4 days

MSAFP results consistent with increased risk of NTD may be followed-up with appropriate diagnostic testing as detailed in the report. MSAFP does not screen for chromosomal abnormalities.

Reference Range
AFP MoM:  
NTD <2.50
IDD <1.90
TWINS <4.00

Clinical Significance
Maternal serum alpha-fetoprotein (MSAFP) is used for prenatal screening. Maternal serum Alpha-Fetoprotein (AFP) elevation is associated with open neural tube defects, multiple gestation, placental anomalies, ventral abdominal wall defects, congenital nephrosis, and oligohydramnios. Follow-up for abnormal AFP results include genetic counseling, level II or III ultrasound examination and consideration of amniocentesis for chromosome and AFP analysis. MSAFP is not to be used as a screening test for chromosomal abnormalities.

Performing Laboratory
Quest Diagnostics Nichols Institute San Juan Capistrano
33608 Ortega Hwy
San Juan Capistrano, CA 92675-2042

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.